Obesity-related heart failure with preserved ejection fraction: diagnostic and therapeutic challenges

키워드

참고문헌 (60)

1. Jin Joo Park, "Current status of heart failure: global and Korea", The Korean Journal of Internal Medicine, 35(3), pp.487~497 (2020), 대한내과학회[DOI]
2. Park Jin Joo, "Heart Failure Statistics in Korea, 2020: A Report from the Korean Society of Heart Failure", International Journal of Heart Failure, 3(4), pp.224~ (2021), 대한심부전학회[DOI]
3. Owan TE, "Trends in prevalence and outcome of heart failure with preserved ejection fraction", N Engl J Med, 355, pp.251~259 (2006)
4. Vasan RS, "Epidemiology of left ventricular systolic dysfunction and heart failure in the framingham study : an echocardiographic study over 3 decades", JACC Cardiovasc Imaging, 11, pp.1~11 (2018)
5. Shah SJ, "Phenotype-specific treatment of heart failure with preserved ejection fraction : a multiorgan roadmap", Circulation, 134, pp.73~90 (2016)
6. Obokata M, "Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction", Circulation, 136, pp.6~19 (2017)
7. Reddy YNV, "A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction", Circulation, 138, pp.861~870 (2018)
8. Pieske B, "How to diagnose heart failure with preserved ejection fraction : the HFA-PEFF diagnostic algorithm : a consensus recommendation from the Heart Failure Association(HFA)of the European Society of Cardiology(ESC)", Eur Heart J, 40, pp.3297~3317 (2019)
9. Hwang IC, "H2FPEF score reflects the left atrial strain and predicts prognosis in patients with heart failure with preserved ejection fraction", J Card Fail, 27, pp.198~207 (2021)
10. Tada A, "Performance of the H2FPEF and the HFA-PEFF scores for the diagnosis of heart failure with preserved ejection fraction in Japanese patients : a report from the Japanese multicenter registry", Int J Cardiol, 342, pp.43~48 (2021)
11. Koichi Egashira, "HFA-PEFF scores: prognostic value in heart failure with preserved left ventricular ejection fraction", The Korean Journal of Internal Medicine, 37(1), pp.96~108 (2022), 대한내과학회[DOI]
12. Ndumele CE, "N-terminal pro-brain natriuretic peptide and heart failure risk among individuals with and without obesity : the atherosclerosis risk in communities(ARIC)study", Circulation, 133, pp.631~638 (2016)
13. Mehra MR, "Obesity and suppressed B-type natriuretic peptide levels in heart failure", J Am Coll Cardiol, 43, pp.1590~1595 (2004)
14. Selvaraj S, "Application of diagnostic algorithms for heart failure with preserved ejection fraction to the community", JACC Heart Fail, 8, pp.640~653 (2020)
15. Obokata M, "Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction : a simultaneous invasive-echocardiographic study", Circulation, 135, pp.825~838 (2017)
16. McDonagh TA, "2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure", Eur Heart J, 42, pp.3599~3726 (2021)
17. Ha JW, "Diastolic stress test : invasive and noninvasive testing", JACC Cardiovasc Imaging, 13(1 Pt 2), pp.272~282 (2020)
18. Jung MH, "Decreases in left atrial compliance during early-stage exercise are related to exercise intolerance in asymptomatic significant mitral stenosis", Echocardiography, 34, pp.1633~1639 (2017)
19. Lewis GD, "Pulmonary vascular response patterns during exercise in left ventricular systolic dysfunction predict exercise capacity and outcomes", Circ Heart Fail, 4, pp.276~285 (2011)
20. Lancellotti P, "The clinical use of stress echocardiography in non-ischaemic heart disease : recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography", Eur Heart J Cardiovasc Imaging, 17, pp.1191~1229 (2016)
21. Pandey A, "Physical activity, fitness, and obesity in heart failure with preserved ejection fraction", JACC Heart Fail, 6, pp.975~982 (2018)
22. Hall JE, "Obesity-induced hypertension : interaction of neurohumoral and renal mechanisms", Circ Res, 116, pp.991~1006 (2015)
23. Wang TJ, "Impact of obesity on plasma natriuretic peptide levels", Circulation, 109, pp.594~600 (2004)
24. Packer M, "Obesity-related heart failure with a preserved ejection fraction : the mechanistic rationale for combining inhibitors of aldosterone, neprilysin, and sodium-glucose cotransporter-2", JACC Heart Fail, 6, pp.633~639 (2018)
25. Briones AM, "Adipocytes produce aldosterone through calcineurin-dependent signaling pathways : implications in diabetes mellitus-associated obesity and vascular dysfunction", Hypertension, 59, pp.1069~1078 (2012)
26. Huby AC, "Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis", Circulation, 132, pp.2134~2145 (2015)
27. Kenchaiah S, "Pericardial fat and the risk of heart failure", J Am Coll Cardiol, 77, pp.2638~2652 (2021)
28. Rao VN, "Regional adiposity and risk of heart failure and mortality : the Jackson heart study", J Am Heart Assoc, 10, pp.e020920~ (2021)
29. Ayton SL, "Epicardial adipose tissue in obesity-related cardiac dysfunction", Heart, 108, pp.339~344 (2022)
30. Jung MH, "Effects of sarcopenia, body mass indices, and sarcopenic obesity on diastolic function and exercise capacity in Koreans", Metabolism, 97, pp.18~24 (2019)
31. Lee SY, "Sex-related differences among young adults with heart failure : Does sex matter?", Int J Cardiol, 364, pp.91~92 (2022)
32. Jung MH, "Sex-specific associations of obesity with exercise capacity and diastolic function in Koreans", Nutr Metab Cardiovasc Dis, 31, pp.254~262 (2021)
33. Meyer TE, "Long-term caloric restriction ameliorates the decline in diastolic function in humans", J Am Coll Cardiol, 47, pp.398~402 (2006)
34. Kitzman DW, "Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction : a randomized clinical trial", JAMA, 315, pp.36~46 (2016)
35. Pandey A, "Exercise training in patients with heart failure and preserved ejection fraction : meta-analysis of randomized control trials", Circ Heart Fail, 8, pp.33~40 (2015)
36. Miranda WR, "Impact of bariatric surgery on quality of life, functional capacity, and symptoms in patients with heart failure", Obes Surg, 23, pp.1011~1015 (2013)
37. Shimada YJ, "Bariatric surgery and emergency department visits and hospitalizations for heart failure exacerbation : population-based, self-controlled series", J Am Coll Cardiol, 67, pp.895~903 (2016)
38. Mikhalkova D, "Bariatric surgery-induced cardiac and lipidomic changes in obesity-related heart failure with preserved ejection fraction", Obesity(Silver Spring), 26, pp.284~290 (2018)
39. Anker SD, "Empagliflozin in heart failure with a preserved ejection fraction", N Engl J Med, 385, pp.1451~1461 (2021)
40. Nassif ME, "The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction : a multicenter randomized trial", Nat Med, 27, pp.1954~1960 (2021)
41. Packer M, "Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure", Circulation, 136, pp.1548~1559 (2017)
42. Zelniker TA, "Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors : JACC state-ofthe-art review", J Am Coll Cardiol, 75, pp.422~434 (2020)
43. Braunwald E, "Gliflozins in the management of cardiovascular disease", N Engl J Med, 386, pp.2024~2034 (2022)
44. Cowie MR, "SGLT2 inhibitors : mechanisms of cardiovascular benefit beyond glycaemic control", Nat Rev Cardiol, 17, pp.761~772 (2020)
45. Lambers Heerspink HJ, "Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes", Diabetes Obes Metab, 15, pp.853~862 (2013)
46. Storgaard H, "Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes : a systematic review and meta-analysis", PLoS One, 11, pp.e0166125~ (2016)
47. Schork A, "Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes : a prospective study using bioimpedance spectroscopy", Cardiovasc Diabetol, 18, pp.46~ (2019)
48. Ferrannini E, "Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2diabetes", Diabetes, 65, pp.1190~1195 (2016)
49. Verma S, "Empagliflozin increases cardiac energy production in diabetes : novel translational insights into the heart failure benefits of SGLT2 inhibitors", JACC Basic Transl Sci, 3, pp.575~587 (2018)
50. Requena-Ibáñez JA, "Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF : from the EMPA-TROPISM study", JACC Heart Fail, 9, pp.578~589 (2021)
51. Mullens W, "Empagliflozin-induced changes in epicardial fat : the centerpiece for myocardial protection?", JACC Heart Fail, 9, pp.590~593 (2021)
52. Packer M, "Role of deranged energy deprivation signaling in the pathogenesis of cardiac and renal disease in states of perceived nutrient overabundance", Circulation, 141, pp.2095~2105 (2020)
53. Maejima Y, "SGLT2 inhibitors play a salutary role in heart failure via modulation of the mitochondrial function", Front Cardiovasc Med, 6, pp.186~ (2020)
54. Ye Y, "SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3", ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor, 2017, pp.31, 119~132
55. Cohen JB, "Clinical phenogroups in heart failure with preserved ejection fraction : detailed phenotypes, prognosis, and response to spironolactone", JACC Heart Fail, 8, pp.172~184 (2020)
56. Pitt B, "Spironolactone for heart failure with preserved ejection fraction", N Engl J Med, 370, pp.1383~1392 (2014)
57. Elkholey K, "Effect of obesity on response to spironolactone in patients with heart failure with preserved ejection fraction", Am J Cardiol, 146, pp.36~47 (2021)
58. Hong-Mi Choi, "Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence", The Korean Journal of Internal Medicine, 35(3), pp.498~513 (2020), 대한내과학회[DOI]
59. Solomon SD, "Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction", N Engl J Med, 381, pp.1609~1620 (2019)
60. Vaduganathan M, "A putative placebo analysis of the effects of sacubitril", valsartan in heart failure across the full range of ejection fraction, 2020, pp.41, 2356~2362

관련 논문AI추천